Cost-utility of Focal HIFU vs Prostatectomy

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer

Key facts

Study ID

NCT05710861

Run by

University Hospital, Bordeaux

People needed

346

Starts

2023-03-06

Expected to finish

2029-06-22

Last updated by the study team

2026-04-09

Who can join

Age: 50 and older, up to 75. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 45-75 yo male harboring a non-treated localized prostatic adenocarcinoma of maximum Gleason score 3+4, ISUP 2 unilateral on at most maximum 2 contiguous sextants (favorable intermediate risk),with or without ipsilateral or contralateral focus of score 3+3 (ISUP1).
• Tumor visible on MRI and proven by systematic and/or targeted biopsies according to the center's practices, regardless of the route used (transrectal or transpirenal)
• Or patients under active surveillance whose follow-up prostate biopsies reveal unilateral ISUP2 on at most 2 contiguous sextants (favorable intermediate risk), with or without ipsilateral or contralateral Gleason 3+3 focus (ISUP1)
• Patients with several suspicious foci on MRI may be be included if only one of these foci is confirmed by targeted biopsies with an ISUP2 score. If more than one suspected site on MRI is confirmed by targeted biopsies, these should be unilateral ISUP2 on a maximum of 2 contiguous sextants (favourable intermediate risk), with or without an ipsilateral or contralateral site with a Gleason score of 3+3 (ISUP1).
• stage T1c-T2,
• with PSA <20 ng/ml,
• with prostate volume less than 150 ml,
• patient clearly informed of the study and having agreed, with sufficient time for reflection to participate by signing the study's informed consent form,
• patient affiliated to or benefiting from a social security scheme

You may not qualify if…

• Metastatic prostate cancer.
• Gleason score > 3+4 (ISUP>2).
• Adenoma prostate carcinoma Cribriform or intraductal.
• Previous treatment anterior for the same cancer, whatever modality.
• Contra-indication to pelvic MRI with gadolinium injection.
• Contra-indication to surgery or general anesthesia.
• Patient who refuse the one-year follow-up control biopsy after F-HIFU.
• Presence of implant (stent, catheter) less than 1 cm from the treatment area.
• Urinary or rectal fistula.
• Anal or rectal stenosis or any other abnormality that may interfere with the Focal One® endorectal probe introduction.
• Anatomic abnormality of the rectum or rectal mucosa.
• Presence of a urinary artificial sphincter, a penile prosthesis or intraprostatic implant, i.e. urethral prosthesis.
• Bladder neck and/or urethral stenosis or sclerosis.
• Inflammatory bowel disease (colon or rectum).
• Ongoing UTI (should be treated before the F-HIFU or the RP).
• Previous anal or rectal surgery that may interfere with the anal probe introduction.
• Latex allergy.
• Rectal wall thickness > 10 mm.
• Tumor not accessible to a F-HIFU treatment (tumors located in the fibro-muscular anterior zone).
• Previous not controlled cancer and/or treated since less than 5 years (except basocellular skin cancer).
• Patient not able to understand the trial objectives or refusing to adhere to the trial instructions.
• Patients under law-protection.
• Patient in an ongoing research trial.
• Patient with a severe health or psychologic problem that could impair the protocol pathway.

Where it is running

• Clinique Saint Vincent — Besançon, France (enrolling)
• Clinique Tivoli — Bordeaux, France (enrolling)
• CHU de Bordeaux — Bordeaux, France (enrolling)
• CHU Toulouse rangueil — Toulouse, France (enrolling)
• Clinique Oceane — Vannes, France (enrolling)
• CHU Grenoble Alpes — Grenoble, France (enrolling)
• Hopital prive drome ardeche — Guilherand-Granges, France (enrolling)
• Hopital Claude HURIEZ — Lille, France (enrolling)
• Hopital Privé La Louviere — Lille, France (enrolling)
• Hopital Edouard Herriot Pavillon V — Lyon, France (enrolling)
• APHM Nord Marseille — Marseille, France (enrolling)
• Hopital Cochin — Paris, France (enrolling)
• Hopital Privé francheville — Périgueux, France (enrolling)
• Hopital Lyon Sud HCL Bat 3C Centre — Pierre-Bénite, France (enrolling)
• Clinique La Croix du Sud — Quint-Fonsegrives, France (enrolling)
• CHU de Rennes — Rennes, France (enrolling)
• CH Saintonge — Saint-Jean-d'Angély, France (enrolling)
• Clinique Saint Michel — Toulon, France (enrolling)
• Hopitaux civil de Colmar — Colmar, France
• CHU Pointe à Pitre — Pointe-à-Pitre, Guadeloupe

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.